State Street
CNTA

State Street’s Centessa Pharmaceuticals CNTA Stock Holding History

State Street’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-45,912
Closed -$603K – 4305
2025
Q2 		$603K Sell
45,912
-732
-2% -$9.27K ﹤0.01% 3585
2025
Q1 		$671K Sell
46,644
-1,462
-3% -$23.9K ﹤0.01% 3526
2024
Q4 		$806K Sell
48,106
-486
-1% -$8.05K ﹤0.01% 3530
2024
Q3 		$777K Buy
+48,592
New +$595K ﹤0.01% 3520

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

State Street's CNTA Position: Q3 2025 in Review

State Street sold out of Centessa Pharmaceuticals (CNTA) in Q3 2025, closing a stake of 45,912 shares — an estimated $603K sold.

State Street first reported a position in CNTA in Q3 2024 and held it in 4 quarters. The position peaked at $806K in Q4 2024. 125 funds tracked by Wall St. Rank hold CNTA as of Q3 2025.

  • State Street reported no remaining Centessa Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • State Street sold 45,912 Centessa Pharmaceuticals shares in Q3 2025, an estimated $603K.
  • State Street first reported a position in Centessa Pharmaceuticals in Q3 2024 and held it in 4 quarters.
  • State Street's Centessa Pharmaceuticals position peaked at $806K in Q4 2024.
  • 125 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q3 2025.

Based on State Street's 13F filing for Q3 2025, filed 14 Nov 2025.